Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus

Abstract Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CR...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical colorectal cancer 2014-09, Vol.13 (3), p.145-155
Hauptverfasser: Cheng, Ann-Lii, Li, Jin, Vaid, Ashok K, Ma, Brigette Buig Yue, Teh, Catherine, Ahn, Joong B, Bello, Maximino, Charoentum, Chaiyut, Chen, Li-Tzong, de Lima Lopes, Gilberto, Ho, Gwo F, Kong, Hwai L, Lam, Ka O, Liu, Tian S, Park, Young S, Sriuranpong, Virote, Sudoyo, Aru W, Wang, Jaw-Yuan, Zhang, Jun, Zhang, Su Z, Ciardiello, Fortunato, Köhne, Clause-Henning, Shaw, Michael, Kim, Tae Won
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional ‘real-world’ experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for K RAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available.
ISSN:1533-0028
1938-0674
DOI:10.1016/j.clcc.2014.06.004